The complexity of PTEN: mutation, marker and potential target for therapeutic intervention

Bibliography

• ENG C: PTEN: One gene, many syndromes. Hum. Mutat (2003) 22:183–198.
   PubMed Web of Science ®Google Scholar
• •A well-written review giving insight to PTEN and related diseases.
   Google Scholar
• HILL C, HUNTER SB, BRAT DJ: Genetic markers in glioblastoma: prognostic significance and future therapeutic implications. Adv. Anat. Pathol. (2003) 10:212–217.
   PubMedGoogle Scholar
• SHERBET GV, PATIL D: Genetic abnormalities of cell proliferation, invasion and metastasis, with special reference to gynecological cancers. Anticancer Res. (2003) 23:1357–1371.
   PubMed Web of Science ®Google Scholar
• PARSONS R, SIMPSON L: PTEN and cancer. Methods Mol. Biol. (2003) 222:147–166.
   PubMedGoogle Scholar
• •A review that focuses on the effects of PTEN on cancer.
   Google Scholar
• HARADA N, SUGIMURA T, YOSHIMURA R et al.: Novel germline mutation of the PTEN gene in a Japanese family with Cowden disease. Gastroenterol. (2003) 38:87–91.
   Google Scholar
• KNOBBE CB, MERLO A, REIFENBERGER G: PTEN signaling in gliomas. Neurooncol. (2002) 4:196–211.
   Google Scholar
• YAMADA KM, ARAKI M: Tumor suppressor PTEN: modulator of cell signaling, growth, migration and apoptosis. J. Cell Sci. (2001) 114:2375–2382.
   PubMed Web of Science ®Google Scholar
• DOWNES CP, BENNETT D, MCCONNACHIE G et al: Antagonism of PI 3-kinase-dependent signaling pathways by the tumour suppressor protein, PTEN. Biochem. Soc. Trans. (2001) 29:846–851.
   Google Scholar
• RAFTOPOULOU M, ETIENNE-MANNEVIELLE S, SELF Aet al: Regulation of cell migration by the C2 domain of the tumor suppressor PTEN. Science (2004) 303:1179–1181.
   PubMed Web of Science ®Google Scholar
• CHANG F, LEE JT, NAVOLANIC P et al:Involvement of the PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia (2003) 17:590–603.
   PubMed Web of Science ®Google Scholar
• STECK PA, PERSHOUSE MA, JASSER SA et al.: Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat. Genet. (1997) 15:356–362.
   Google Scholar
• •This paper gives a comprehensive study of PTEN and its identity.
   Google Scholar
• TORRES J, PULIDO R: The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus. Implications for PTEN stability to proteasome-mediated degradation. J Biol. Chem. (2001) 276:993–998.
   Google Scholar
• TORRES J, RODRIGUEZ J, MYERS MP et al: Phosphorylation-regulated cleavage of the tumor suppressor PTEN by caspase-3: implications for the control of protein stability and PTEN-protein interactions. J. Biol. Chem. (2003) 278:30652–30660.
   PubMedGoogle Scholar
• MYERS MP, TONKS NK: PTEN: sometimes taking it off can be better than putting it on. Am. J. Human Genet. (1997) 61:1234–1238.
   Google Scholar
• MAEHAMA T, DIXON JE: The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J. Biol. Chem. (1998) 273:13375–13378.
   PubMed Web of Science ®Google Scholar
• LI D-M, SUN H: TEP1, encoded by a candidate tumor suppressor locus is a novel protein tyrosine phosphatase regulated by transforming growth factor B. Cancer Res. (1997) 57:2124–2129.
   Google Scholar
• LI J, YEN C, LIAW D et al: PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast and prostate cancer. Science (1997) 275:1943–1947.
   PubMed Web of Science ®Google Scholar
• MYERS MP, STOLAROV J, ENG C et al:P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase. Proc. Nati Acad. Sci. USA (1997) 94:9052–9057.
   PubMed Web of Science ®Google Scholar
• ZHU X, KWON CH, SCHLOSSHAUER PW et al.: PTEN induces G(1) cell cycle arrest and decreases cyclin D3 levels in endometrial carcinoma cells. Cancer Res. (2001) 61:4569–4575.
   PubMed Web of Science ®Google Scholar
• WENG LP, BROWN JL, ENG C: PTEN coordinates G1 arrest by down regulating cyclin D1 via its protein phosphatase activity and up regulating p27 via its lipid phosphatase activity. Hum. Mol. Genet. (2001)10:599–604.
   PubMed Web of Science ®Google Scholar
• WENG LP, BROWN JL, ENG CL: PTEN induces apoptosis and cell cycle arrest through phosphoinosito1-3-kinase/Akt-dependent and independent pathways. Hum. Mol. Genet. (2001)10:237–242.
   PubMed Web of Science ®Google Scholar
• WENG LP, GIMM O, KUM JB et al.: Transient ectopic expression of PTEN in thyroid cancer cell lines induces cell cycle arrest and cell type-dependent cell death. Hum. Mol. Genet. (2001)10:251–258.
   PubMed Web of Science ®Google Scholar
• GINN-PEASE M, ENG C: Increased nuclear phosphatase and tensin homologue deleted on chromosome 10 is associated with GOG1 in MCF-7 cells. Cancer Res. (2003) 63:282–286.
   PubMed Web of Science ®Google Scholar
• ENG C: PTEN: One gene, many syndromes. Hum. Mut. (2003) 22:183–198.
   PubMed Web of Science ®Google Scholar
• WAITE KA, ENG C: Protean PTEN: form and function. Am. I Hum. Genet. (2002) 70:829–844.
   PubMed Web of Science ®Google Scholar
• LAUGHNER E, TAGHAVI P, CHILES K et al.: HER2 (neu signaling increases the rate of hypoxia-inducible factor 1 alpha (1-1IF-1alpha) synthesis: novel mechanism for HIF1-mediated growth factor expression. Mol. Cell Biol. (2001) 21:3995–4004.
   PubMed Web of Science ®Google Scholar
• MAZURE NM, CHEN EY, LADEROUTE KR et al: Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3 kinase/Akt signaling pathway in Ha-Ras-transformed cells through a hyposia inducible factor-1 transcriptional element. Blood (1997) 90:3322–3331.
   PubMed Web of Science ®Google Scholar
• ZHONG H, CHILES K, FELDSER D et al.: Modulation of hypoxia-inducible factor 1 alpha expression by the epidermal growth factor/phosphtidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res. (2000) 60:1541–1545.
   PubMed Web of Science ®Google Scholar
• TSUGAWA K, JONES MK, SUGIMACHI K et al.: Biological role of phosphatase PTEN in cancer and tissue injury healing. Front. Biosci. (2002) 7:245–251.
   PubMed Web of Science ®Google Scholar
• DI CRISTOFANO A, PANDOLFI PP: The multiple roles of PTEN in tumor suppression. Cell (2000) 100:387–390.
   PubMed Web of Science ®Google Scholar
• MUTTER GL: PTEN, a protean tumor suppressor. Am. J. Pathol. (2001) 158:1895–1898.
   PubMedGoogle Scholar
• TROUSSARD AA, MAWJI NM, ONG C et al.: Conditional knock-out of integrin-linked kinase demonstrates and essential role in protein kinase B/Akt activation. J. Biol. Chem. (2003) 278:22374–22378.
   PubMed Web of Science ®Google Scholar
• STEELMAN LS, POHNERT SC, SHELTON JG et al.: JAK/STAT, RAF/MEK/ERK, PI3K/AKT and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia (2004) 18:189–218.
   PubMed Web of Science ®Google Scholar
• RODRIGUES GA, FALASCA M, ZHANG Z et al.: A novel positive feedback loop mediated by the docking protein Gabi and phosphatidylinositol 3-kinase in epidermal growth factor receptor signaling. Mol. Cell. Biol. (2000) 20:1448–1459.
   PubMedGoogle Scholar
• MAHIMAINATHAN L, CHOUDHURY GG: Inactivation of platelet-derived growth factor receptor by the tumor suppressor PTEN provides a novel mechanism of action of the phosphatase. ./. Biol. Chem. (2004) 279:15258–15268.
   PubMed Web of Science ®Google Scholar
• MYERS MP, PASS I, BATTY IH et al.: The lipid phosphatase activity of PTEN is critical for its tumor suppressor function. Proc. Nati Acad. Li. USA (1998) 95:13513–13518.
   PubMed Web of Science ®Google Scholar
• STEELMAN LS, POHNERT SC, SHELTON JG et al.: JAK/STAT, RAF/IVIEK/ERK,PI3K/AKT and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia (2004) 18:189–218.
   PubMed Web of Science ®Google Scholar
• VAZQUEZ F, GROSSMAN SR, TAKAHASHI SR et al.: Phosphorylation of the PTEN tail acts as an inhibitory switch by preventing its recruitment into a protein complex. J. Biol. Chem. (2001) 276:48627–48630.
   PubMed Web of Science ®Google Scholar
• WENG LP, SMITH WM, BROWN JL et al.: PTEN inhibits insulin-stimulated MEK/MAPK activation and cell growth by blocking IRS-1/Grb-2/Sos complex formation in a breast cancer model. Hum. Mol. Genet. (2001) 10:605–616.
   PubMed Web of Science ®Google Scholar
• WENG LP, BROWN JL, BAKER KM et al: PTEN blocks insulin-mediated Ets-2 phosphorylation through MAP kinase, independent of the phosphoinositide-3-kinase pathway. Hum. Mol. Genet. (2002) 11:1687–1696.
   PubMed Web of Science ®Google Scholar
• SIMPSON L, LI J, LIAW D et al: PTEN expression causes a feedback upregulation of IRS-2 signaling. Mol. Cell Biol. (2001) 21:3947–3958.
   PubMedGoogle Scholar
• KAU TR, SCHROEDER F, RAMASWAMY S et al: A chemical genetic screen identifies inhibitors of regulated nuclear export of a Forkhead transcription factor in PTEN-deficient tumor cells. Cancer Cell (2003) 4:463–476.
   PubMed Web of Science ®Google Scholar
• NELSON MR, VAN STAVERN CG, PEETERS EA et al: Germline mutations in the PTEN/MMAC1 gene in patients with Cowden disease. Hum. Mol. Genet. (1997) 6:1383–1387.
   Google Scholar
• MARSH DJ, COULON V, LUNETTA KL et al: Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. Hum. Mol. Genet. (1998) 7:507–515.
   PubMed Web of Science ®Google Scholar
• ROBINSON S, COHEN AR: Cowden disease and Lhermitte-Duclos disease: characterization of a new phakomatosis. Neurosurgery (2000) 46:371–383.
   PubMedGoogle Scholar
• ZORI RT, MARSH DJ, GRAHAM GE et al: Germline PTEN mutation in a family with Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome. Am. J. Med. Genet. (1998) 80:399–402.
   PubMedGoogle Scholar
• KWAK YG, SONG CH, YI HK et al.: Involvement of PTEN in airway hyperresponsiveness and inflammation in bronchial asthma. J. Clin. Invest. (2003) 111:1083–1092.
   PubMed Web of Science ®Google Scholar
• SORIA JC, LEE HY, LEE JI et al.: Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. Clin. Cancer Res. (2002) 5:1178–1184.
   Google Scholar
• SALVESEN HB, MACDONALD N, RYAN A et al.: PTEN methylation is associated with advanced stage and microsatellite instability in endometrial carcinoma. Int. J. Cancer (2001) 91:22–26.
   PubMed Web of Science ®Google Scholar
• •This paper demonstrated that methylation may be involved with PTEN cancers.
   Google Scholar
• KANG YH, LEE HS, KIM WH: Promoter methylation and silencing of PTEN in gastric carcinoma. Lab. Invest. (2002) 82:285–291.
   PubMed Web of Science ®Google Scholar
• TAMURA G: Promoter methylation statusof tumor suppressor and tumor-related genes in neoplastic and non-neoplastic gastric epithelia. Hista lintopathof (2004) 19:221–228.
   Google Scholar
• HERMAN JG: Hypermethylation of tumor suppressor genes in cancer. Semin. Cancer Biol. (1999) 9:359–367.
   PubMed Web of Science ®Google Scholar
• RAZANI B, SCHLEGEL A, LIU J et al: Caveolin-1, a putative tumour suppressor gene. Biochem. Soc. Trans. (2001) 29:494–499.
   PubMed Web of Science ®Google Scholar
• CASELLI A, MAZZINGHI B, CAMICI G et al.: Some protein tyrosine phosphatases target in part to lipid rafts and interact with caveolin-1. Biochem. Biophys. Res. Commun. (2002) 296:692–697.
   PubMed Web of Science ®Google Scholar
• ALDRED MA, GINN-PEASE ME, MORRISON CD et al: Caveolin-1 and caveolin-2, together with three bone morphogenetic protein-related genes may encode novel tumor suppressors down-regulated in sporadic follicular thyroid carcinogenesis. Cancer Res. (2003) 63:2864–2871.
   PubMed Web of Science ®Google Scholar
• LI L, REN CH, TAHIR SA et al: Caveolin-1 maintains activated Akt in prostate cancer cells through scaffolding domain binding site interactions with and inhibition of serine/threonine protein phosphatases PP1 and PP2A. Mol. Biol. (2003) 23:9389–9404.
   Google Scholar
• ALDRED MA, GINN-PEASE ME, MORRISON CD et al.: Caveolin-1 and caveolin-2, together with three bone morphogenetic protein-related genes, may encode novel tumor suppressors down-regulated in sporadic follicular thyroid carcinogenesis. Cancer Res. (2003) 63:2864–2871.
   PubMed Web of Science ®Google Scholar
• FRISK T, FOUKAKIS T, DWIGHT T et al.: Silencing of the PTEN tumor-suppressor gene in anaplastic thyroid cancer. Genes Chromosomes Cancer (2002) 35:74–80.
   PubMed Web of Science ®Google Scholar
• ENG C: Role of PTEN, a lipid phosphatase upstream effector of protein kinase B, in epithelial thyroid carcinogenesis. Ann. N Y Acad. Sci. (2002) 968:213–221.
   PubMed Web of Science ®Google Scholar
• GIMM O, PERREN A, WENG LP et al: Differential nuclear and cytoplasmic expression of PTEN in normal thyroid tissue, and benign and malignant epithelial thyroid tumors. Am. J. Pathol (2000) 156:1693–1700.
   PubMed Web of Science ®Google Scholar
• PARSONS R, MYEROFF LL, LIU B et al:Microsatellite instability and mutations of the transforming growth factor beta type II receptor gene in colorectal cancer. Cancer Res. (1995) 55:5548–5550.
   PubMed Web of Science ®Google Scholar
• DICUONZO G, ANGELETTI S, GARCIA-FONCILLAS J et al.: Colorectal carcinomas and PTEN/MMAC1 gene mutations. Clin. Cancer Res. (2001) 7:4049–4053.
   PubMedGoogle Scholar
• KUISMANEN SA, MOISIO AL, SCHWEIZER P et al: Endometrial and colorectal tumors from patients with hereditary nonpolyposis colon cancer display different patterns of microsatellite instability. Am. J. Pathol (2002) 160:1953–1958.
   Google Scholar
• GUANTI G, RESTA N, SIMONE C et al: Involvement of the PTEN mutations in the genetic pathways of colorectal cancerogensis. Hum. Oncol Genet. (1999) 35:647–651.
   Google Scholar
• SHINK H, PARK YJ, PARK JG: PTEN mutations in colorectal cancers displaying microsatellite instability. Cancer Lett. (2001) 174:189–194.
   Google Scholar
• GOEL A, ARNOLD CN, NIEDZWIECKI D et al.: Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability high sporadic colorectal cancers. Cancer Res. (2004) 64:3014–3021.
   PubMed Web of Science ®Google Scholar
• MAXWELL GL, RISINGER JI, TONG Bet al.: Mutation of the PTEN tumor suppressor gene is not a feature of ovarian cancers. Gynecol OncoL (1998) 70:13–16.
   Google Scholar
• OBATA K, MORLAND SJ, WATSON RH et al.: Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Res. (1998) 58:2095–2097.
   PubMed Web of Science ®Google Scholar
• SCHONDORF T, DOSTAL A, GRABMANN J et al: Single mutations of the PTEN gene in recurrent ovarian carcinomas../. Soc. Gynecol Investig. (2000) 7:313–316.
   Google Scholar
• CHENG JQ, GODWIN AK, BELLACOSA A et al: AKT2, a putative oncogene encoding a member of a subfamily of protein-serineithreonine kinases, is amplified in human ovarian carcinomas. Proc. Natl. Acad. Sci. USA (1992) 89:9267–9271.
   PubMed Web of Science ®Google Scholar
• BELLACOSA A, DE FEO D, GODWIN AK et al: Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int. J. Cancer (1995) 64:280–285.
   PubMed Web of Science ®Google Scholar
• THOMPSON FH, NELSON MA, TRENT JM et al.: Amplification of the 19q13.1-q13.2 sequences in ovarian cancer. G-band, FISH and molecular studies. Cancer Genet. Cytogener (1996) 87:55–62.
   Google Scholar
• RISINGER JI, HAYES AK, BERCHUCK A et al: PTEN/MMAC1 mutations in endometrial cancers. Cancer Res. (1997) 57:4736–4738.
   PubMed Web of Science ®Google Scholar
• TASHIRO H, BLAZES MS, WU R et al: Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res. (1997) 57:3935–3940.
   PubMed Web of Science ®Google Scholar
• LEVINE RL, CARGILE CB, BLAZES MS et al: PTEN mutations and microsatellite instability in complex atypical hyperplasia, a precursor lesion to uterine endometrioid carcinoma. Cancer Res. (1998) 58:3254–3258.
   PubMed Web of Science ®Google Scholar
• MAXWELL GL, RISINGER JI, TONG Bet al: Mutation of the PTEN tumor suppressor gene in endometrial hyperplasias. Cancer Res. (1998) 58:2500–2503.
   PubMed Web of Science ®Google Scholar
• MAIA H Jr, MALTEZ A, ATHAYDE C et al.: Detection of endometrial intraepithelial neoplasia (EIN) in postmenopausal endometrium. Maturitas (2003) 46(2):153–161.
   Google Scholar
• STAMBOLIC V, TSAO MS, MACPHERSON D et al.: High incidence of breast and endometrial neoplasia resembling human Cowden syndrome in PTEN+/- mice. Cancer Res. (2000) 60:3605–3611.
   PubMed Web of Science ®Google Scholar
• •PTEN and its involvement in breast and endometrial cancer, which seem to resemble CD.
   Google Scholar
• KANAMORI Y, KIGAWA J, ITAMOCHI H et al: Correlation between loss of PTEN expression and Akt phosphorylation in endometrial carcinoma. Clin. Cancer Res. (2001) 7:892–895.
   PubMed Web of Science ®Google Scholar
• WAN X, YOKOYAMA Y, SHINOHARA A et al: PTEN augments staurosporine-induced apoptosis in PTEN-null Ishikawa cells by downregulating PI3K/Akt signaling pathway. Cell Death Differ. (2002) 9:414–420.
   Google Scholar
• TERAKAWA N, KANAMORI Y, YOSHIDA S: Loss of PTEN expression followed by Akt phosphorylation is a poor prognostic factor for patients with endometrial cancer. Endocr. Relat. Cancer (2003) 10:203–208.
   PubMed Web of Science ®Google Scholar
• WU XSK, NESHAT MS, WHANG YE et al.: The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc. Natl. Acad. Li. USA (1998) 95:15587–15591.
   Google Scholar
• FEILOTTER HE, NAGAI MA, BOAG AH et al.: Analysis of PTEN and the 10q23 region in primary prostate carcinomas. Oncogene (1998) 16: 1743-1748.
   Google Scholar
• MCMENAMIN ME, SOUNG P, PERERA S et al.: Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res. (1999) 59:4291–4296.
   PubMed Web of Science ®Google Scholar
• ZHENG XY, DING W, XIE LP et al: Correlation of Skp2 and p27 (kip].) protein expression and clinicopathological features of prostate cancer. Ai. Zheng (2004) 23:215–218.
   Google Scholar
• YANG G, AYALA G, DEMARZO A et al.:Elevated Skp2 protein expression in human prostate cancer: association with loss of the cyclin-dependent kinase inhibitor p27 and PTEN and with reduced recurrence-free survival. Clin. Cancer Res. (2002) 8:3419–3426.
   PubMed Web of Science ®Google Scholar
• VAN BRUSSEL JP, VAN STEENBRUGGE GJ, ROMIJN JC et al.: Chemosensitivity of prostate cancer cell lines and expression of multidrug resistance-related proteins. Eur. J. Cancer (1999) 35:664–671.
   PubMed Web of Science ®Google Scholar
• LEE JT, STEELMAN LS, MCCUBREY JA: PI3K activation leads to MRP-1 expression and subsequent chemoresistance in advanced prostate cancer. Cancer Res. (2004) In Press.
   Google Scholar
• GRUNWALD V, DEGRAFFENRIED L, RUSSEL D et al.: Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer Res. (2002) 62:6141–6145.
   PubMed Web of Science ®Google Scholar
• •Inhibitors are shown in this paper to reverse doxorubicin resistance, which may help therapeutically in prostate cancer.
   Google Scholar
• HUANG H, CHEVILLE JC, PAN Y et al.: PTEN induces chemosensitivity in PTEN-mutated prostate cancer cells by suppression of Bc1-2 expression. J. Biol. Chem. (2001) 276:38830–38836.
   PubMed Web of Science ®Google Scholar
• TIWARI G, SAKAUE H, POLLACK JR et al: Gene expression profiling in prostate cancer cells with Akt activation reveals Fra-1 as an Akt-inducible gene. Mol. Cancer Res. (2003) 1:475–484.
   Google Scholar
• DEOCAMPO ND, HUANG H, TINDALL DJ: The role of PTEN in the progression and survival of prostate cancer. Minerva Endocrinol. (2003) 28:145–153.
   PubMedGoogle Scholar
• PERREN A, WENG LP, BOAG AH et al: Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am. J. Pathol. (1999) 155:1253–1260.
   PubMed Web of Science ®Google Scholar
• DAHIA PL, FITZGERALD MD, ZHANG X et al: A highly conserved processed PTEN pseudogene is located on chromosome band 9p21. Oncogene (1998) 16:2403–2406.
   PubMedGoogle Scholar
• BYUN DS, CHO K, RYU BK et al: Frequent monoallelic deletion of PTEN and its reciprocal association with PIK3CA amplification in gastric carcinoma. bit.j Cancer (2003) 104:318–327.
   PubMed Web of Science ®Google Scholar
• YOKOYAMA Y, WAN X, SHINOHARA A et al: Expression of PTEN and PTEN pseudogene in endometrial carcinoma. bit.j Mol. Med. (2000) 6:47–50.
   Google Scholar
• ZYSMAN MA, CHAPMAN WB, BAPAT B: Considerations when analyzing the methylation status of PTEN tumor suppressor gene. Am. J. Pathol. (2002) 160:795–800.
   PubMed Web of Science ®Google Scholar
• SEHGAL SN, BAKER H, ENG CF etal.:Demethoxyrapamycin (AY-24,668), a new antifungal antibiotic. .1 Antibiot. (1983) 36:351–354.
   Google Scholar
• DANCEY JE: Clinical development of mammalian target of rapamycin inhibitors. Hematol. Oncol. Clin. North Am. (2002) 16:1101–1114.
   PubMed Web of Science ®Google Scholar
• SEHGAL SN: Rapamune (RAPA, rapamycin, sirolimus): mechanism of activation and immunosuppressive effects result from blockade of signal transduction and inhibition of cell cycle progression. Chit. Biochem. (1998) 31:335–340.
   Google Scholar
• PROUD CG, WANG X, PATEL JV et al: Interplay between insulin and nutrients in the regulation of translation factors. Biochem. Soc. Trans. (2001) 29:541–547.
   Google Scholar
• PODSYPANINA K, LEE RT, POLITIS C et al.: An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice. Proc. Natl. Acad. Sci. USA (2001) 98:10320–10325.
   PubMed Web of Science ®Google Scholar
• YU K, TORAL-BARZA L, DISCAFANI C et al.: mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr. Relat. Cancer (2001) 8:249–258.
   PubMed Web of Science ®Google Scholar
• GINGRAS AC, GYGI SP, RAUGHT B et al.: Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism. Genes Dev. (1999) 13:1422–1437.
   PubMed Web of Science ®Google Scholar
• PERALBA JM, DEGRAFFENRIED L, FRIEDRICHS W et al: Pharmacodynamic evaluation of CCI-779, an inhibitor of mTOR, in cancer patients. CM]. Cancer Res. (2003) 9:2887–2892.
   PubMed Web of Science ®Google Scholar
• GU J, TAMURA M, YAMADA KM: Tumor suppressor PTEN inhibits integrin-and growth factor mediated mitogen-activated protein (MAP) kinase signaling pathways. J. Cell. Biol. (1998) 143:1375–1383.
   PubMed Web of Science ®Google Scholar
• TAMURA M, GU J, TAKINO T et al: Tumor suppressor PTEN inhibition of cell invasion, migration and growth: differential involvement of focal adhesion kinase and p130Cas. Cancer Res. (1999) 59:442–449.
   PubMed Web of Science ®Google Scholar
• TAMURA M, GU J, DANEN EH et al: PTEN interactions with focal adhesion kinase and suppression of the extracellular matrix-dependent phosphatidylinositiol 3-kinase/Akt cell survival pathway. J. Biol. Chem. (1999) 274:20693–20703.
   PubMed Web of Science ®Google Scholar
• MAEHAMA T, OKAHARA F, KANAHO Y: The tumor suppressor PTEN: involvement of a tumor suppressor candidate protein in PTEN turnover. Biochem. Soc. Trans. (2004) 32:343–347.
   PubMed Web of Science ®Google Scholar
• NING K, PEI L, LIAO M et al: Dual neuroprotective signaling mediated by downregulating two distinct phosphatase activities of PTEN. Neurosci (2004) 16:4052–4060.
   Google Scholar
• PERREN A, KOMMINOTH P, SAREMASLANI P et al: Mutation and expression analysis reveals differential subcellular compartmentalization of PTEN in endocrine pancreatic tumors compared to normal islet cells. Am. I Pathol. (2000) 157:1097–1103.
   PubMed Web of Science ®Google Scholar
• FREEMAN DJ, LI AG, WEI A etal.: PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase dependent and independent mechanisms. Cancer Cell (2003) 3:117–130.
   Google Scholar